[1]曹程王 庆凯 杨宝刚 马明静.系统性红斑狼疮ABCG1和GALNT2基因启动子区甲基化的临床意义[J].心血管病学进展,2021,(12):1148-1153.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.021]
　CAO Cheng,WANG Qingkai,YANG Baogang,et al.Clinical Significance of ABCG1 and GALNT2 Gene Promoter Methylation in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2021,(12):1148-1153.[doi:10.16806/j.cnki.issn.1004-3934.2021.12.021]
点击复制

系统性红斑狼疮ABCG1和GALNT2基因启动子区甲基化的临床意义()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年12期
页码:
1148-1153
栏目:
论著
出版日期:
2021-12-25

文章信息/Info

Title:
Clinical Significance of ABCG1 and GALNT2 Gene Promoter Methylation in Systemic Lupus Erythematosus
作者:
曹程王 庆凯 杨宝刚 马明静
(河北省沧州中西医结合医院心内科,河北 沧州 061001)
Author(s):
CAO Cheng;  WANG Qingkai;  YANG Baogang;  MA Mingjing
?Department of Cardiology,Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Cangzhou 061001,Hebei,China)
关键词:
系统性红斑狼疮; 肺动脉压; ABCG1; GALNT2; 启动子; DNA甲基化; 预后
Keywords:
Systemic lupus erythematosus;  Pulmonary hypertension;  ABCG1;  GALNT2;  Promoter;  DNA methylation;  Prognosis
DOI:
10.16806/j.cnki.issn.1004-3934.2021.12.021
摘要:
目的 探讨ABCG1和GALNT2基因启动子区甲基化在系统性红斑狼疮（SLE）中的临床意义。方法 选取2014年1月2017年1月河北省沧州中西医结合医院收治SLE患者123例，以是否发生（PH）分为合并PH组（SLE-PH组）不合并PH组（SLE-noPH组），比较两组患者临床资料和ABCG1、GALNT2基因启动子区甲基化情况，采用Kaplan-Meier生存分析ABCG1、GALNT2基因启动子区甲基化SLE患者3年生存率变化，采用向前法COX模多因素分析SLE、SLE-PH患者不良预后危险因素。结果 SLE-PH组雷诺现象、活动后胸闷、指端血管炎构成比和右心室内径、右心房上下径、右心房左右径、肺动脉宽度、SLE疾病活动（SLEDAI）、ABCG1甲基化比率、GALNT2甲基化比率均显著于SLE-noPH组（P0.05），而左心室内径和美国纽心脏病协会（NYHA）分级（-Ⅱ）构成比显著于SLE-noPH组（P0.05）。ABCG1甲基化组平均生存时间显著于ABCG1非甲基化组（Log-Rank χ2=4.076，P=0.043）。SLE患者中，死亡组雷诺现象、肺间质病变、ABCG1甲基化比率和右心室内径、右心房上下径、右心房左右径、动脉宽度、SLEDAI均显著于存活组（P0.05），而NYHA分级（-Ⅱ）构成比率显著于存活组（P0.05）；在SLE-PH患者中，死亡组雷诺现象构成比率和SLEDAI均显著于存活组（P0.05），而NYHA分级（-Ⅱ）构成比率显著于存活组（P0.05）。NYHA分级（~Ⅳ）、SLEDAI（20分）、ABCG1甲基化是SLE患者不良预后的危险因素（P0.05），NYHA分级（~Ⅳ）是SLE-PH患者不良预后的危险因素（P0.05）。结论 ABCG1、GALNT2甲基化在SLE-PH呈水平，ABCG1甲基化会增加SLE患者不良预后风险，GALNT2、ABCG1甲基化对SLE-PH不良预后影响不明显。
Abstract:
Objective To explore the clinical significance of ABCG1 and GALNT2 gene promoter methylation in systemic lupus erythematosus (SLE). Methods A total of 123 patients with SLE admitted in Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from January 2014 to January 2017 were enrolled,and divided into PH combination (SLE-PH) and non-PH combination (SLE-noPH) group. Clinical data,ABCG1 and GALNT2 gene promoter methylation were compared between both groups. Changes in 3-year survival rate of SLE patients with ABCG1 and GALNT2 gene promoter methylation were assessed by Kaplan-Meier survival analysis. Risk factors for poor prognosis were calculated by forward multivariate COX regression analysis. Results The proportions of Raynaud’s phenomenon (PRP),chest tightness after activity and fingertip vasculitis,right ventricular diameter (RVD),suprainferior diameter of right atrium (SDRA),left and right diameter of right atrium (LRRA),pulmonary artery width,SLE disease activity index (SLEDAI),proportions of ABCG1 and GALNT2 methylation in SLE-PH group were significantly higher than SLE-noPH group (P＜0.05),with a lower left ventricular diameter and proportion of New York Heart Association (NYHA) classⅠ-Ⅱ(P＜0.05). The average survival time was shorter in ABCG1 methylation group than non-methylation (Log-Rank χ2=4.076,P=0.043). For SLE patients,PRP,interstitial lung disease,ABCG1 methylation,RVD,SDRA,LRRA,arterial width and SLEDAI in death group were higher than survival group (P＜0.05),with a lower proportion of NYHA classⅠ-Ⅱ(P＜0.05). For SLE-PH patients,PRP and SLEDAI score in death group were higher than the survival (P＜0.05),with a lower proportion of NYHA classⅠ-Ⅱ(P＜0.05). NYHA classⅢ~Ⅳ,SLEDAI≥20 points and ABCG1 methylation were risk factors for poor prognosis of SLE (P＜0.05),and NYHA classⅢ~Ⅳfor poor prognosis of SLE-PH (P＜0.05). Conclusion The methylation levels of ABCG1 and GALNT2 gene promoters are high in SLE-PH patients. ABCG1 methylation will increase risk for poor prognosis of SLE, while the effects of GALNT2 and ABCG1 methylation on poor prognosis of SLE-PH seem not significant.

参考文献/References:

[1].La Paglia GMCLeone MC,Lepri G,et al. One year in review 2017:systemic lupus erythematosus[J]. Clin Exp Rheumatol,2017,35(4):551-561.
[2].Di Battista M,Marcucci E,Elefante E,et al. One year in review 2018:systemic lupus erythematosus[J]. Clin Exp Rheumatol,2018,36(5):763-777.
[3].Rivas-Larrauri F,Yamazaki-Nakashimada MA. Systemic lupus erythematosus:Is it one disease?[J]. Reumatol Clin,2016,12(5):274-281.
[4].Rhodes CJ,Batai K,Bleda M,et al. Genetic determinants of risk in pulmonary arterial hypertension:international genome-wide association studies and meta-analysis[J]. Lancet Respir Med,2019,7(3):227-238.
[5].McLaughlin VV,Hoeper MM,Channick RN,et al. Pulmonary arterial hypertension-related morbidity is prognostic for mortality[J]. J Am Coll Cardiol,2018,71(7):752-763.
[6].Xu RH,Wei W,Krawczyk M,et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma[J]. Nat Mater,2017,16(11):1155-1161.
[7].Richard MA,Huan T,Ligthart S,et al. DNa methylation analysis identifies loci for blood pressure regulation[J]. Am J Hum Genet,2017,101(6):888-902.
[8].Ligthart S,Marzi C,Aslibekyan S,et al. DNA methylation signatures of chronic low-grade inflammation are associated with complex diseases[J]. Genome Biol,2016,17(1):255-269.
[9].Simonneau C,Calie N,Rubin U,et al. Clinical classification of pulmonary hypertension[J]. J Am Coil Cardiol,2004,43(12 Suppl S):5S-12S.
[10].D?rner T,Furie R. Novel paradigms in systemic lupus erythematosus[J]. Lancet,2019,393(10188):2344-2358.
[11].Chen L,Morris DL,Vyse TJ. Genetic advances in systemic lupus erythematosus:an update[J]. Curr Opin Rheumatol,2017,29(5):423-433.
[12].Wang J,Qian J,Wang Y,et a1. Serological biomarkers as risk factors of SLE-associated pulmonary artefial hypertension:a systematic review and meta-analysis[J]. Lupus,2017,26(13):1390-1400.
[13].Kommireddy S,Bhyravavajhala S,Kurimeti K,et a1. Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy:an observational study[J]. Rheumatology,2015,54(9):1673-1679.
[14].Morales-Cano D,Callejo M,Barreira B,et al. Elevated pulmonary arterial pressure in Zucker diabetic fatty rats[J]. PLoS One,2019,14(1):e0211281.
[15].Qian J,Wang Y,Huang C,et a1. Survival and prognostic factors of systemic lupus erythematosus-associated pulmonary arterial hypertension:a PRISMA-compliant systematic review and meta. analysis[J]. Autoimmun Rev,2016,15(3):250-257.
[16].Zhang N,Li M,Qian J,et al. Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study:baseline characteristics and risk factors[J]. Int J Rheum Dis,2019,22(5):921-928.
[17].Sayols-Baixeras S,Subirana I,Lluis-Ganella C,et al. Identification and validation of seven new loci showing differential DNA methylation related to serum lipid profile:an epigenome-wide approach. The REGICOR study[J]. Hum Mol Genet,2016,25(20):4556-4565.
[18].Marucci A,Antonucci A,De Bonis C,et al. GALNT2 as a novel modulator of adipogenesis and adipocyte insulin signaling[J]. Int J Obes (Lond),2019,43(12):2448-2457.
[19].Di Paola R,Marucci A,Trischitta V. GALNT2 effect on HDL-cholesterol and triglycerides levels in humans:Evidence of pleiotropy?[J]. Nutr Metab Cardiovasc Dis,2017,27(4):281-282.
[20].Hautefort A,Chesné J,Preussner J,et al. Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension[J]. Oncotarget,2017,8(32):52995-53016.
[21].Chung SM,Lee CK,Lee EY,et a1. Clinical aspects of pulmonary hypertension in patients with systemic lupus erythematosus and in patients with idiopathic pulmonary arterial hypertension[J]. Clin Rheumatol,2006,25(6):866-872.

相似文献/References:

[1]徐学萍 汪汉 蔡琳.结缔组织病相关心脏瓣膜病[J].心血管病学进展,2019,(9):1267.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.021]
　XU Xueping,WANG Han,CAI Lin.Connective Tissue Disease-associated Valvular Heart Disease[J].Advances in Cardiovascular Diseases,2019,(12):1267.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.021]
[2]秦莉,张艺文,杨晓倩,等.系统性红斑狼疮合并心力衰竭的危险因素及管理[J].心血管病学进展,2020,(3):264.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.012]
　QIN Li,ZHANG Yiwen,YANG Xiaoqian,et al.Risk Factors and Management of Heart Failure in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2020,(12):264.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.012]
[3]秦莉 张艺文 杨晓倩 王燕凤 汪汉.系统性红斑狼疮合并心力衰竭的发病机制及病因[J].心血管病学进展,2020,(4):381.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.013]
　QIN Li,ZHANG Yiwen,YANG Xiaoqian,et al.The Pathogenesis and Etiology of Heart Failure in Systemic lupus Erythematosus[J].Advances in Cardiovascular Diseases,2020,(12):381.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.013]
[4]张艺文 汪汉 秦莉 杨晓倩 童兰 蔡琳.狼疮患者冠心病的诊断、风险评估和治疗[J].心血管病学进展,2020,(5):513.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.017]
　ZHANG Yiwen,WANG Han,QIN Li,et al.Diagnosis, Risk Evaluation and Therapy of Coronary Heart Disease in Lupus Patients[J].Advances in Cardiovascular Diseases,2020,(12):513.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.017]
[5]蒲华霞 彭礼清.系统性红斑狼疮心脏受累的MRI评价进展[J].心血管病学进展,2021,(8):716.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.011]
　PU huaxia,PENG Liqing.Magnetic Resonance Imaging in the Evaluation of Cardiac Involvement in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2021,(12):716.[doi:10.16806/j.cnki.issn.1004-3934.2021.08.011]
[6]谭运择 智琲琲 王清清 罗松 蔡军.系统性红斑狼疮肺动脉高压无创影像学研究现状与进展[J].心血管病学进展,2022,(12):1101.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.010]
　TAN Yunze,ZHI Beibei,WANG Qingqing,et al.Noninvasive Imaging Study of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus[J].Advances in Cardiovascular Diseases,2022,(12):1101.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.010]

备注/Memo

备注/Memo:
基金项目：沧州市重点研发计划指导项目（172302031）
通信作者：曹程E-mail：caocheng135@163.com?/div>
收稿时间：2021-04-21
更新日期/Last Update: 2022-01-07